EDIT - エディタス・メディシン (Editas Medicine Inc.) エディタス・メディシン

 EDITのチャート


 EDITの企業情報

symbol EDIT
会社名 Editas Medicine Inc (エディタス・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エディタス・メディシン(Editas Medicine Inc.)はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復(CRISPR)技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9(Cas9)またはPrevotellaおよびFrancisella 1(Cpf1)由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸(RNA)複合体を使用し、特定のデオキシリボ核酸(DNA)配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10(LCA10)のゲノム編集治療薬を開発している。   エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子ゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。  As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
本社所在地 11 Hurley Street Cambridge MA 02141 USA
代表者氏名 James C. Mullen ジェームスC.ミューレン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9000
設立年月日 41518
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 112人
url www.editasmedicine.com
nasdaq_url https://www.nasdaq.com/symbol/edit
adr_tso
EBITDA EBITDA(百万ドル) -131.47100
終値(lastsale) 27.88
時価総額(marketcap) 1329196954.72
時価総額 時価総額(百万ドル) 1323.476
売上高 売上高(百万ドル) 21.24800
企業価値(EV) 企業価値(EV)(百万ドル) 112.34
当期純利益 当期純利益(百万ドル) -132.45000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense).

 EDITのテクニカル分析


 EDITのニュース

   Why Editas Medicine Stock Is Jumping Today | The Motley Fool  2021/06/28 16:17:15 The Motley Fool
Good news for Intellia was viewed as good news for Editas.
   Why Editas Medicine Stock Is Jumping 13.9% This Week  2021/06/25 10:01:00 The Motley Fool
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.
   Enrollment underway in Editas Medicine''s pediatric cohort of EDIT-101 study in inherited retinal disorder  2021/06/23 11:38:36 Seeking Alpha
   Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer  2021/06/15 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Companys newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D. In connection with the appointments, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to each of Drs. Shearman and Li as inducements material to their entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). Drs. Shearmans and Lis stock options provide for the purchase of up to 52,718 shares and 44,202 shares, respectively, of Editas Medicine common stock at a price of $38.53 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vest over four years, with 25 percent of the shares vesting on the first anniversary of each individuals employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to their continued service relationship with Editas Medicine through the applicable vesting dates.
   Editas Medicine names new chief science and chief regulatory officers  2021/06/14 13:14:46 Seeking Alpha
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?
   Booming CAGR of 20.8%, CRISPR and CAS Gene Market to Surpass US$ 7,603.8 Million by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc  2021/03/23 11:13:10 OpenPR
A new market study on the 2020-2027 CRISPR and CAS Gene Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report
   CRISPR and CAS Gene Market – Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript  2021/03/02 07:34:47 OpenPR
CRISPR and CAS Gene Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Editas Medicine (NASDAQ:EDIT) Issues Quarterly Earnings Results  2021/02/26 16:09:01 Transcript Daily
Editas Medicine (NASDAQ:EDIT) posted its quarterly earnings data on Thursday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.19), MarketWatch Earnings reports. The company had revenue of $11.42 million during the quarter, compared to analyst estimates of $5.64 million. Editas Medicine had a negative return on […]
   Editas Medicine Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/02/24 15:28:00 Stock Market Daily
Editas Medicine announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Better Buy: CRISPR Therapeutics vs. Editas Medicine  2021/02/05 11:10:00 The Motley Fool
Which of these two hot gene therapy stocks is the better buy?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エディタス・メディシン EDIT Editas Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)